1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Biologics Development
  6.  » Accelerated Pathways: Strategies to Manage and Maximize Across the Development Cycle

Accelerated Pathways: Strategies to Manage and Maximize Across the Development Cycle

Summary: While accelerated development programs are intense by design, few have a similar regulatory experience—particularly when it comes to Breakthrough Therapy Designation (BTD). In this executive summary, industry experts from Alnylam® Pharmaceuticals, Mirum Pharmaceuticals, Catalent Biologics and UroGen® Pharma share case studies of how they’ve adapted to increasingly expedited regulatory reviews.

 

Click here to download the Executive Summary